Citations (56)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Tao Lu & Jai Prakash. (2021) Nanomedicine Strategies to Enhance Tumor Drug Penetration in Pancreatic Cancer. International Journal of Nanomedicine 16, pages 6313-6328.
Read now
Read now
Yun Wang, Long Cui, Peter Georgiev, Latika Singh, Yanyan Zheng, Ying Yu, Jeff Grein, Chunsheng Zhang, Eric S. Muise, David L. Sloman, Heidi Ferguson, Hongshi Yu, Cristina St. Pierre, Pranal J Dakle, Vincenzo Pucci, James Baker, Andrey Loboda, Doug Linn, Christopher Brynczka, Doug Wilson, Brian B Haines, Brian Long, Richard Wnek, Svetlana Sadekova, Michael Rosenzweig, Andrew Haidle, Yongxin Han & Sheila H. Ranganath. (2021) Combination of EP4 antagonist MF-766 and anti-PD-1 promotes anti-tumor efficacy by modulating both lymphocytes and myeloid cells. OncoImmunology 10:1.
Read now
Read now
Wesley R Samore & Christopher S Gondi. (2014) Brief overview of selected approaches in targeting pancreatic adenocarcinoma. Expert Opinion on Investigational Drugs 23:6, pages 793-807.
Read now
Read now
Randall J Kimple, Suzanne Russo, Arta Monjazeb & A William Blackstock. (2012) The role of chemoradiation for patients with resectable or potentially resectable pancreatic cancer. Expert Review of Anticancer Therapy 12:4, pages 469-480.
Read now
Read now
Piotr Hogendorf, Adam Durczyński, Anna Kumor & Janusz Strzelczyk. (2012) Prostaglandin E2 (PGE2) in Portal Blood in Patients with Pancreatic Tumor—A Single Institution Series. Journal of Investigative Surgery 25:1, pages 8-13.
Read now
Read now
Malte Buchholz & Thomas M Gress. (2009) Molecular changes in pancreatic cancer. Expert Review of Anticancer Therapy 9:10, pages 1487-1497.
Read now
Read now
Articles from other publishers (50)
Ruiyang Ren, Chenyi Xiong, Runyu Ma, Yixuan Wang, Tianyang Yue, Jiayun Yu & Bin Shao. (2023) The recent progress of myeloid‐derived suppressor cell and its targeted therapies in cancers. MedComm 4:4.
Crossref
Crossref
Behnia Akbari, Tahereh Soltantoyeh, Zahra Shahosseini, Farhad Jadidi-Niaragh, Jamshid Hadjati, Christine E. Brown & Hamid Reza Mirzaei. (2023) PGE2-EP2/EP4 signaling elicits mesoCAR T cell immunosuppression in pancreatic cancer. Frontiers in Immunology 14.
Crossref
Crossref
S. M. Adnan Ali, Yumna Adnan, Saleema Mehboob Ali, Zubair Ahmad, Tabish Chawla & Hasnain Ahmed Farooqui. (2022) Immunohistochemical analysis of a panel of cancer stem cell markers and potential therapeutic markers in pancreatic ductal adenocarcinoma. Journal of Cancer Research and Clinical Oncology 149:6, pages 2279-2292.
Crossref
Crossref
Kaka Renaldi, Marcellus Simadibrata, Nur Rahadiani, Diah Rini Handjari, Alida Roswita Harahap, Kuntjoro Harimurti, Nasrul Zubir, Lianda Siregar, Imelda Maria Loho, Evlina Suzanna, Bonita Prawirodihardjo, Heriawaty Hidajat, Budi Widodo, Alphania Rahniayu, Renaningtyas Tambun, Andy William & Dadang Makmun. (2023) The Expressions of NF−κB, COX−2, Sp1, and c−Jun in Pancreatic Ductal Adenocarcinoma and Their Associations with Patient Survival. Pathophysiology 30:2, pages 92-109.
Crossref
Crossref
Johanna Bödder, Leanne M. Kok, Jonathan A. Fauerbach, Georgina Flórez-Grau & I. Jolanda M. de Vries. (2023) Tailored PGE2 Immunomodulation of moDCs by Nano-Encapsulated EP2/EP4 Antagonists. International Journal of Molecular Sciences 24:2, pages 1392.
Crossref
Crossref
Sepideh Mirzaei, Mohammad Hossein Gholami, Hui Li Ang, Farid Hashemi, Ali Zarrabi, Amirhossein Zabolian, Kiavash Hushmandi, Masoud Delfi, Haroon Khan, Milad Ashrafizadeh, Gautam Sethi & Alan Prem Kumar. (2021) Pre-Clinical and Clinical Applications of Small Interfering RNAs (siRNA) and Co-Delivery Systems for Pancreatic Cancer Therapy. Cells 10:12, pages 3348.
Crossref
Crossref
Sofia M. Clemente, Oscar H. Martínez-Costa, Maria Monsalve & Alejandro K. Samhan-Arias. (2020) Targeting Lipid Peroxidation for Cancer Treatment. Molecules 25:21, pages 5144.
Crossref
Crossref
Łukasz Kuźbicki & Anna A. Brożyna. (2019) Immunohistochemical detectability of cyclooxygenase‐2 expression in cells of human melanocytic skin lesions: A methodological review. Journal of Cutaneous Pathology 47:4, pages 363-380.
Crossref
Crossref
Daniel Ansari, William Torén, Qimin Zhou, Dingyuan Hu & Roland Andersson. (2019) Proteomic and genomic profiling of pancreatic cancer. Cell Biology and Toxicology 35:4, pages 333-343.
Crossref
Crossref
Ganji Purnachandra Nagaraju & Bassel F. El‐Rayes. (2019) Cyclooxygenase‐2 in gastrointestinal malignancies. Cancer 125:8, pages 1221-1227.
Crossref
Crossref
Johan Fagman, David Ljungman, Peter Falk, Britt‑Marie Iresj�, Cecilia Engstr�m, Peter Naredi & Kent Lundholm. (2019) EGFR, but not COX‑2, protein in resected pancreatic ductal adenocarcinoma is associated with poor survival. Oncology Letters.
Crossref
Crossref
Weiqi Hu, Weimin Xu, Yi Shi & Weijun Dai. (2018) lncRNA HOTAIR upregulates COX-2 expression to promote invasion and migration of nasopharyngeal carcinoma by interacting with miR-101. Biochemical and Biophysical Research Communications 505:4, pages 1090-1096.
Crossref
Crossref
Hiroyuki Matsubayashi, Keiko Sasaki, Sachiyo Ono, Masato Abe, Hirotoshi Ishiwatari, Akira Fukutomi, Katsuhiko Uesaka & Hiroyuki Ono. (2018) Pathological and Molecular Aspects to Improve Endoscopic Ultrasonography–Guided Fine-Needle Aspiration From Solid Pancreatic Lesions. Pancreas 47:2, pages 163-172.
Crossref
Crossref
Yong Cui, Xiao-Ou Shu, Hong-Lan Li, Gong Yang, Wanqing Wen, Yu-Tang Gao, Qiuyin Cai, Nathaniel Rothman, Hui-Yong Yin, Qing Lan, Yong-Bing Xiang & Wei Zheng. (2017) Prospective study of urinary prostaglandin E2 metabolite and pancreatic cancer risk. International Journal of Cancer 141:12, pages 2423-2429.
Crossref
Crossref
Haiming Sun, Xuelong Zhang, Donglin Sun, Xueyuan Jia, Lidan Xu, Yuandong Qiao & Yan Jin. (2017) COX-2 expression in ovarian cancer: an updated meta-analysis. Oncotarget 8:50, pages 88152-88162.
Crossref
Crossref
Michele T. Yip-Schneider, Rosalie A. Carr, Huangbing Wu & C. Max Schmidt. (2017) Prostaglandin E 2 : A Pancreatic Fluid Biomarker of Intraductal Papillary Mucinous Neoplasm Dysplasia. Journal of the American College of Surgeons 225:4, pages 481-487.
Crossref
Crossref
Ann E. Zeleniak, Wei Huang, Mary K. Brinkman, Melissa L. Fishel & Reginald Hill. (2017) Loss of MTSS1 results in increased metastatic potential in pancreatic cancer. Oncotarget 8:10, pages 16473-16487.
Crossref
Crossref
James A. McCubrey, Dariusz Rakus, Agnieszka Gizak, Linda S. Steelman, Steve L. Abrams, Kvin Lertpiriyapong, Timothy L. Fitzgerald, Li V. Yang, Giuseppe Montalto, Melchiorre Cervello, Massimo Libra, Ferdinando Nicoletti, Aurora Scalisi, Francesco Torino, Concettina Fenga, Luca M. Neri, Sandra Marmiroli, Lucio Cocco & Alberto M. Martelli. (2016) Effects of mutations in Wnt/β-catenin, hedgehog, Notch and PI3K pathways on GSK-3 activity—Diverse effects on cell growth, metabolism and cancer. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1863:12, pages 2942-2976.
Crossref
Crossref
Wilson Petrushnko, Justin S. Gundara, Philip R. De Reuver, Greg O'Grady, Jaswinder S. Samra & Anubhav Mittal. (2016) Systematic review of peri-operative prognostic biomarkers in pancreatic ductal adenocarcinoma. HPB 18:8, pages 652-663.
Crossref
Crossref
JING LI, OU LI, MUJIE KAN, MING ZHANG, DAN SHAO, YUE PAN, HUILIN ZHENG, XUEWEN ZHANG, LI CHEN & SONGYAN LIU. (2015) Berberine induces apoptosis by suppressing the arachidonic acid metabolic pathway in hepatocellular carcinoma. Molecular Medicine Reports 12:3, pages 4572-4577.
Crossref
Crossref
Dingbo Shi, Xiangsheng Xiao, Yun Tian, Lijun Qin, Fangyun Xie, Rui Sun, Jingshu Wang, Wenbin Li, Tianze Liu, Yao Xiao, Wendan Yu, Wei Guo, Yuqing Xiong, Huijuan Qiu, Tiebang Kang, Wenlin Huang, Chong Zhao & Wuguo Deng. (2014) Activating enhancer-binding protein-2α induces cyclooxygenase-2 expression and promotes nasopharyngeal carcinoma growth. Oncotarget 6:7, pages 5005-5021.
Crossref
Crossref
Ewa Pomianowska, Aasa R Schjølberg, Ole Petter F Clausen & Ivar P Gladhaug. (2014) COX-2 overexpression in resected pancreatic head adenocarcinomas correlates with favourable prognosis. BMC Cancer 14:1.
Crossref
Crossref
Ewa Pomianowska, Dagny Sandnes, Krzysztof Grzyb, Aasa R Schj?lberg, Monica Aasrum, Ingun H Tveteraas, Vegard Tjomsland, Thoralf Christoffersen & Ivar P Gladhaug. (2014) Inhibitory effects of prostaglandin E2on collagen synthesis and cell proliferation in human stellate cells from pancreatic head adenocarcinoma. BMC Cancer 14:1.
Crossref
Crossref
Di Wang, Xiao-Zhong Guo, Hong-Yu Li, Jia-Jun Zhao, Xiao-Dong Shao & Chun-Yan Wu. (2014) Prognostic significance of cyclooxygenase-2 protein in pancreatic cancer: a meta-analysis. Tumor Biology 35:10, pages 10301-10307.
Crossref
Crossref
Shuixiang He, Guifang Lu, Helei Hou, Zhenjun Zhao, Zhanfang Zhu, Xinlan Lu, Jinghong Chen & Zhilun Wang. (2014) Saikosaponin‑d suppresses the expression of cyclooxygenase‑2 through the phospho‑signal transducer and activator of transcription 3/hypoxia‑inducible factor‑1α pathway in hepatocellular carcinoma cells. Molecular Medicine Reports.
Crossref
Crossref
Sandra J. Schmid, Marie-Charlotte Glatzel, Claudia Welke, Marko Kornmann, Alexander Kleger, Thomas F. E. Barth, Simone Fulda, Jochen K. Lennerz & Peter Möller. (2013) Absence of FLICE-Inhibitory Protein Is a Novel Independent Prognostic Marker for Very Short Survival in Pancreatic Ductal Adenocarcinoma. Pancreas 42:7, pages 1114-1119.
Crossref
Crossref
Xinyan Wang, Yu Liang, Jun Wang & Min Wang. (2013) RETRACTED ARTICLE: Effect of NS-398, a cyclooxygenase-2 selective inhibitor, on the cytotoxicity of cytotoxic T lymphocytes to ovarian carcinoma cells. Tumor Biology 34:3, pages 1517-1522.
Crossref
Crossref
Giuseppe Aprile, Claudio Avellini, Michele Reni, Micol Mazzer, Luisa Foltran, Diego Rossi, Stefano Cereda, Emiliana Iaiza, Gianpiero Fasola & Andrea Piga. (2012) Biglycan expression and clinical outcome in patients with pancreatic adenocarcinoma. Tumor Biology 34:1, pages 131-137.
Crossref
Crossref
Dharmalingam Subramaniam, Giridharan Periyasamy, Sivapriya Ponnurangam, Debarshi Chakrabarti, Aravind Sugumar, Muralidhara Padigaru, Scott J. Weir, Arun Balakrishnan, Somesh Sharma & Shrikant Anant. (2012) CDK-4 Inhibitor P276 Sensitizes Pancreatic Cancer Cells to Gemcitabine-Induced Apoptosis. Molecular Cancer Therapeutics 11:7, pages 1598-1608.
Crossref
Crossref
Ann H. Rosendahl, Chinmay Gundewar, Katarzyna Said, Emelie Karnevi & Roland Andersson. (2012) Celecoxib synergizes human pancreatic ductal adenocarcinoma cells to sorafenib-induced growth inhibition. Pancreatology 12:3, pages 219-226.
Crossref
Crossref
M. J. D. Prins, R. J. J. Verhage, F. J. W. ten Kate & R. van Hillegersberg. (2012) Cyclooxygenase Isoenzyme-2 and Vascular Endothelial Growth Factor are Associated with Poor Prognosis in Esophageal Adenocarcinoma. Journal of Gastrointestinal Surgery 16:5, pages 956-966.
Crossref
Crossref
Dharmalingam Subramaniam, Nathan D. Nicholes, Animesh Dhar, Shahid Umar, Vibhudutta Awasthi, Danny R. Welch, Roy A. Jensen & Shrikant Anant. (2011) 3,5-Bis(2,4-Difluorobenzylidene)-4-piperidone, a Novel Compound That Affects Pancreatic Cancer Growth and Angiogenesis. Molecular Cancer Therapeutics 10:11, pages 2146-2156.
Crossref
Crossref
Vegard Tjomsland, Anna Spångeus, Johanna Välilä, Per Sandström, Kurt Borch, Henrik Druid, Sture Falkmer, Ursula Falkmer, Davorka Messmer & Marie Larsson. (2011) Interleukin 1α Sustains the Expression of Inflammatory Factors in Human Pancreatic Cancer Microenvironment by Targeting Cancer-Associated Fibroblasts. Neoplasia 13:8, pages 664-IN3.
Crossref
Crossref
D Ansari, A Rosendahl, J Elebro & R Andersson. (2011) Systematic review of immunohistochemical biomarkers to identify prognostic subgroups of patients with pancreatic cancer. British Journal of Surgery 98:8, pages 1041-1055.
Crossref
Crossref
Nigel B. Jamieson, C. Ross Carter, Colin J. McKay & Karin A. Oien. (2011) Tissue Biomarkers for Prognosis in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-analysis. Clinical Cancer Research 17:10, pages 3316-3331.
Crossref
Crossref
José Eduardo M. Cunha, Marcos V. Perini & Daniela Freitas. 2012. Cancer Metastasis. Cancer Metastasis
333
343
.
A Handra-Luca, S-M Hong, K Walter, C Wolfgang, R Hruban & M Goggins. (2011) Tumour epithelial vimentin expression and outcome of pancreatic ductal adenocarcinomas. British Journal of Cancer 104:8, pages 1296-1302.
Crossref
Crossref
Vegard Tjomsland, Anna Sp?ngeus, Per Sandstr?m, Kurt Borch, Davorka Messmer & Marie Larsson. (2010) Semi Mature Blood Dendritic Cells Exist in Patients with Ductal Pancreatic Adenocarcinoma Owing to Inflammatory Factors Released from the Tumor. PLoS ONE 5:10, pages e13441.
Crossref
Crossref
Francisco J. Padillo, Juan F. Ruiz-Rabelo, Adolfo Cruz, María D. Perea, Inmaculada Tasset, Pedro Montilla, Isaac Túnez & Jordi Muntané. (2010) Melatonin and celecoxib improve the outcomes in hamsters with experimental pancreatic cancer. Journal of Pineal Research 49:3, pages 264-270.
Crossref
Crossref
Nathan G. Richards, David W. Rittenhouse, Boris Freydin, Joseph A. Cozzitorto, Dane Grenda, Hallgeir Rui, Greg Gonye, Eugene P. Kennedy, Charles J. Yeo, Jonathan R. Brody & Agnieszka K. Witkiewicz. (2010) HuR Status is a Powerful Marker for Prognosis and Response to Gemcitabine-Based Chemotherapy for Resected Pancreatic Ductal Adenocarcinoma Patients. Annals of Surgery 252:3, pages 499-506.
Crossref
Crossref
Min Wang, Zhumei Shi, Dan Liu, Gong-Yu Zhang, Jiahao Sha & Bing-Hua Jiang. (2010) Inhibition of vascular endothelial growth factor expression by Chinese medicine of Hedyotis diffusa Willd herbal compounds. Frontiers in Biology 5:4, pages 361-368.
Crossref
Crossref
Desmond P. Toomey, Ellen Manahan, Ciara McKeown, Annamarie Rogers, Helen McMillan, Michael Geary, Kevin C. Conlon & Joseph F. Murphy. (2010) Vascular Endothelial Growth Factor and not Cyclooxygenase 2 Promotes Endothelial Cell Viability in the Pancreatic Tumor Microenvironment. Pancreas 39:5, pages 595-603.
Crossref
Crossref
Noriyuki Omura, Margaret Griffith, Audrey Vincent, Ang Li, Seung-Mo Hong, Kimberly Walter, Michael Borges & Michael Goggins. (2010) Cyclooxygenase-Deficient Pancreatic Cancer Cells Use Exogenous Sources of Prostaglandins. Molecular Cancer Research 8:6, pages 821-832.
Crossref
Crossref
Hung Pham, Monica Chen, Aihua Li, Jonathan King, Eliane Angst, David W. Dawson, Jenny Park, Howard A. Reber, O. Joe Hines & Guido Eibl. (2010) Loss of 15-Hydroxyprostaglandin Dehydrogenase Increases Prostaglandin E2 in Pancreatic Tumors. Pancreas 39:3, pages 332-339.
Crossref
Crossref
Amanda F. Baker & Tomislav Dragovich. 2010. Drug Discovery in Pancreatic Cancer. Drug Discovery in Pancreatic Cancer
271
289
.
Susan Li Er Loong, Jacqueline Siok Gek Hwang, Hui Hua Li, Joseph Tien Seng Wee, Swee Peng Yap, Melvin Lee Kiang Chua, Kam Weng Fong & Terence Wee Kiat Tan. (2009) Weak expression of cyclooxygenase-2 is associated with poorer outcome in endemic nasopharyngeal carcinoma: analysis of data from randomized trial between radiation alone versus concurrent chemo-radiation (SQNP-01). Radiation Oncology 4:1.
Crossref
Crossref
Subhash Padhye, Sanjeev Banerjee, Deepak Chavan, Shubhangini Pandye, K.Venkateswara Swamy, Shadan Ali, Jing Li, Q. Ping Dou & Fazlul H. Sarkar. (2009) Fluorocurcumins as Cyclooxygenase-2 Inhibitor: Molecular Docking, Pharmacokinetics and Tissue Distribution in Mice. Pharmaceutical Research 26:11, pages 2438-2445.
Crossref
Crossref
John P. Hoffman & Karyn B. Stitzenberg. (2009) Preoperative Versus Postoperative Adjuvant Therapy for Adenocarcinoma of the Pancreas. Advances in Surgery 43:1, pages 189-198.
Crossref
Crossref
Marketa Hermanova, Petr Karasek, Rudolf Nenutil, Michal Kyr, Jiri Tomasek, Ivana Baltasova & Petr Dite. (2009) Clinicopathological Correlations of Cyclooxygenase-2, MDM2, and p53 Expressions in Surgically Resectable Pancreatic Invasive Ductal Adenocarcinoma. Pancreas 38:5, pages 565-571.
Crossref
Crossref
Tomohiko Adachi, Yoshitsugu Tajima, Tamotsu Kuroki, Takehiro Mishima, Amane Kitasato, Noritsugu Tsuneoka & Takashi Kanematsu. 2009. Hepatobiliary and Pancreatic Carcinogenesis in the Hamster. Hepatobiliary and Pancreatic Carcinogenesis in the Hamster
171
181
.